1. Original Papers

  2. (1)Capello D, Scandurra M, Poretti G, Rancoita PMV, Mian M, Gloghini A, Deambrogi C, Martini M, Rossi D, Greiner TC, Chan WC, Ponzoni M, Montes Moreno S, Piris MA, Canzonieri V, Spina M, Tirelli U, Inghirami G, Rinaldi A, Zucca E, Dalla Favera R, Cavalli F, Larocca LM, Kwee I, Carbone A, Gaidano G, & Bertoni F. Genome wide DNA-profiling of HIV-related B-cell lymphomas. British Journal of Haematology 2009: in press.

  3. (2)Scandurra M, Rossi D, Deambrogi C, Rancoita PMV, Chigrinova E, Mian M, Cerri M, Rasi S, Sozzi E, Forconi F, Ponzoni M, Montes-Moreno S, Piris MA, Inghirami G, Zucca E, Gattei V, Rinaldi A, Kwee I, Gaidano G, & Bertoni F. Genomic profiling of Richter’s syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. Hematological Oncology 2009: in press.

  4. (3)Forconi F, Sozzi E, Cencini E, Zaja F, Intermesoli T, Stelitano C, Rigacci L, Gherlinzoni F, Cantaffa R, Baraldi A, Gallamini A, Zaccaria A, Pulsoni A, Gobbi M, Tassi M, Raspadori D, Leoncini L, Rinaldi A, Sabattini E, Bertoni F,  Pileri S, & Lauria F. Hairy cell leukemias (HCL) with unmutated IgHV genes define the minor subset refractory to single agent Cladribine and with more aggressive behavior. Blood 2009: in press.

  5. (4)Bomben R, Dal Bo M, Benedetti D, Capello D, Forconi F, Marconi D, Bertoni F, Maffei R, Laurenti L, Rossi R, Del Principe MI, Luciano F, Sozzi E, Cattarossi I, Zucchetto A, Rossi FM, Bulian P, Zucca E, Nicoloso MS, Degan M, Marasca R, Efremov DG, Del Poeta G, Gaidano G, & Gattei V. Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. Clinical Cancer Research; in press.

  6. (5)Bomben R, Dal Bo M, Capello D, Forconi F, Bertoni F, Maffei R, Laurenti L, Rossi D, Zucca E, Degan M, Marasca R, Efremov DG, Del Poeta G, Gaidano G & Gattei V. IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. British Journal of Haematology 2009: in press.

  7. (6)Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PMV, Compagno M, Cerri M, Rossi D, Murty VV, Zucca E, Gaidano G, Dalla Favera R, Pasqualucci L, Bhagat G & Bertoni F. The NF-ΚB negative regulator TNFAIP3 (A20) is commonly inactivated by somatic mutations and genomic deletions in marginal zone B-cell lymphomas. Blood 2009; 113(20): 4918-4921.

  8. (7)Rancoita PMV, Hutter M, Bertoni F, & Kwee I. Bayesian DNA copy number analysis. BMC Bioinformatics 2009 Jan 8: 10:10 (19 pages).

  9. (8)Compagno M, Lim WK, Grunn A, Nandula SV, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla Favera R, Pasqualucci L. Mutations at multiple genes cause deregulation of the NF-kB pathway in diffuse large B-cell lymphoma. Nature 2009;459(7247):717-21.

  10. (9)Tibiletti MG, Martin V, Bernasconi B, Del Curto B, Pecciarini L, Uccella S, Pruneri G, Ponzoni M, Mazzucchelli L, Martinelli G, Ferreri A, Pinotti G,Assannelli A, Scandurra M,  Doglioni C, Zucca E, Capella C, & Bertoni F. BCL2, BCL6, MYC, MALT1 and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of FISH probes and correlation with clinical outcome. Human Pathology 2009; 40 (5): 645-652.

  11. (10)Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, De Paoli L, Laurenti L, Maffei R, Forconi F, Bertoni F, Zucca E, Agostinelli C, Cabras A, Lucioni M, Martini M, Magni M, Deaglio S, Ladetto M, Nomdedeu J, Besson C, Ramponi A, Canzonieri V, Paulli M, Marasca R, Larocca LM, Carbone A, Pileri SA, Gattei V, & Gaidano G. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clinical Cancer Research 2009; 15(13): 4415-4422.

  12. (11)Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I, Todoerti K, Verdelli D, Battaglia C, Bertoni F, Lambertenghi Deliliers G, & Neri A. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect.  Genes, Chromosomes and Cancer 2009; 48(7):603-14.

  13. (12)Rossi D, Sozzi E, Puma A, De Paoli L, Rasi S, Spina V, Gozzetti A, Tassi M, Cencini E, Raspadori D, Pinto V, Bertoni F, Gattei V,  Lauria F, Gaidano G, Forconi F.  The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. British Journal Haematology 2009;146(1):64-75.

  14. (13)Rossi R, Rasi S, Franceschetti S, Capello D, Castelli A, De Paoli L, Ramponi A, Chiappella A, Pogliani EM, Vitolo U, Kwee I, Bertoni F, Conconi A, & Gaidano G. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 2009; 23(6):1118-26.

  15. (14)Stathis A, Chini C, Bertoni F, Proserpio I, Capella C, Mazzucchelli L, Cavalli F, Pinotti G, & Zucca E. Long-term outcome following Helicobacter pylori eradication in a series of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Annals of Oncology 2009;20(6):1086-93.

  16. (15)Hitz F, Martinelli G, Zucca E, von Moos R, Mingrone W, Simcock M, Peterson J, Cogliatti SB, Bertoni F, Zimmermann DR & Ghielmini M on behalf of SAKK. A multicenter phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. Hematological Oncology 2009; in press.

  17. (16)Bomben R, Dal-Bo M, Capello D, Forconi F, Maffei R, Laurenti L, Rossi D, Del-Principe MI, Zucchetto A, Bertoni F, Rossi, FM, Bulian B, Cattarossi I, Ilariucci F, Sozzi E, Spina V, Zucca E, Degan D, Lauria F, Del-Poeta G, Efremov DG, Marasca R, Gaidano G, & Gattei VG. Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B cell receptors: results from an Italian multicenter study.  British Journal Haematology 2009: 144 (4): 492-506.

  18. (17)Forconi F, Rinaldi A, Kwee I, Sozzi E, Raspadori D, Rancoita PMV, Scandurra M, Rossi D, Deambrogi C, Capello D, Zucca E, Marconi D, Bomben R, Gattei V, Lauria F, Gaidano G & Bertoni F. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. British Journal Haematology 2008; 143(4): 532-536.

  19. (18)Forconi F, Poretti G, Kwee I, Sozzi E, Rossi D, Rancoita PMV, Capello D, Rinaldi A, Zucca E, Raspadori D, Spina V, Lauria F, Gaidano G & Bertoni F. High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. British Journal Haematology 2008; 141(5): 622-630.

  20. 19)Lozza L, Rivino L, Guarda G, Jarrossay D, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A, & Geginat J. The strength of T cell stimulation determines IL-7 responsiveness, secondary expansion and lineage commitment of primed human CD4+IL-7Rhi T cells. European Journal of Immunology 2008; 38(1): 30-39.

  21. 20)Cresta S, Sessa C, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A, Bertoni F, Viganò L, Maur M, Capri G, Maccioni E, Tosi D, & Gianni L. Phase I of bortezomib with weekly paclitaxel in patients with advanced solid tumors. European Journal Of Cancer 2008; 44(13): 1829-1834.

  22. 21)Furlan D, Sahnane N, Carnevali I, Cerutti R, Bertoni F, Kwee I, Uccella S, Bertolini V, Chiaravalli AM & Capella C. Up-regulation of the HIF-1 transcriptional pathway in colorectal carcinomas. Human Pathology 2008; 39 (10): 1483-1494.

  23. 22)Pruneri G, Alietti A Agnelli L, Morabito F, Laszlo D, Calabrese L, Fabris S, Bertolini F, Agazzi A, Bottiglieri L Rafaniello Raviele P Baldini L, Pileri S, M.D., Sabattini E, Bosari S, Maisonneuve P, Lambertenghi-Deliliers G, Bertoni F, Martinelli G, Viale G & Neri A. Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. Leukemia Research 2008; 32(10): 1628-1632.

  24. 23)Fabris S, Todoerti K, Mosca L, Agnelli L, Intini D, Lionetti M, Guerneri S, Lambertenghi-Deliliers G, Bertoni F & Neri A. Molecular and Transcriptional Characterization of the Novel 17p11.2-p12 Amplicon in Multiple Myeloma. Genes, Chromosomes and Cancer 2007;  46 (12): 1109-1118.

  25. 24)Lacrima K, Rinaldi A, Vignati S, Martin V, Tibiletti MG, Gaidano G, Catapano CV & Bertoni F. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B cell lymphomas. Leukemia and Lymphoma 2007; 48(1): 158-167.

  26. 25)Gracia E, Froesch P, Mazzucchelli L, Martin V, Rodríguez-Abreu D, Jiménez J, Melgares M, Santos D, Capó V, Cavalli F, Zucca E & Bertoni F. Low prevalence of Chlamydia psittaci in ocular adnexal lymphomas from Cuban patients. Leukemia and Lymphoma 2007; 48(1): 104-108.

  27. 26)Rinaldi A, Poretti G, Kwee I, Zucca E, Catapano CV, Tibiletti MG & Bertoni F. Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma. Leukemia and Lymphoma 2007; 48(2): 410-412.

  28. 27)Tibiletti MG, Milani K, Martin V, Zucca E, Motta T, Cortelazzo S, Pinotti G, Mazzucchelli L, Pruneri G, Martinelli G, Barbazza R, Capella C & Bertoni F on behalf of the International Extranodal Lymphoma Study Group (IELSG). Chromosome instability and translocation t(11;18) in primary gastric marginal zone B-cell lymphoma of MALT-type. Hematological Oncology 2007; 25: 184-188.

  29. 28)Ponzoni M, Kwee I, Mazzucchelli L, Ferreri AJM, Zucca E, Doglioni C, Cavalli F, &  Bertoni F. A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals. Pathobiology 2007; 74(4): 264-269.

  30. 29)Lombardi K, Poretti G, Mattioli M, Fabris S, Agnelli L, Bicciato S, Kwee I, Rinaldi A, Ronchetti D, Verdelli D, Lambertenghi-Deliliers G, Bertoni F & Neri A. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes, Chromosomes and Cancer 2007; 46(3): 226-238.

  31. 30)Li L, Ryser S, Dizin E, Pils D, Krainer M, Jefford CE, Bertoni F, Zellinger R & Irminger-Finger I. Oncogenic BARD1 Isoforms Expressed in Gynecological Cancers. Cancer Research 2007; 67(24): 11876–11885.

  32. 31)Agnelli L, Bicciato S, Fabris S, Baldini L, Morabito F, Intini D, Verdelli D, Callegaro A, Bertoni F, Lambertenghi-Deliliers G, Lombardi L & Neri A. Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. Haematologica 2007; 92:56-65.

  33. 32)Ponzoni M, Berger F, Chassagne-Clement C, Tinguely M, Jouvet A, Ferreri AJM, Dell’Oro S, Terreni MR, Doglioni C, Weis J, Cerati M, Milani M, Iuzzolino P,  Motta T, Carbone A, Pedrinis E, Sanchez J, Blay JY, Reni M, Conconi A, Bertoni F, Zucca E, Cavalli F, & Borisch  B. on behalf of the International Extranodal Lymphoma Study group (IELSG). Reactive perivascular T-cell infiltrate predicts survival in primary CNS B-cell lymphomas. British Journal Haematology 2007; 138(3): 316-23.

  34. 33)Campidelli C, Sabattini E, Piccioli M, Rossi M, De Blasi D, Miraglia E, Rodriguez-Abreu D, Franscini LL, Bertoni F, Mazzucchelli L, Cavalli F, Zucca E, Pileri SA. Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases. Human Pathology 2007; 38(5): 787-92.

  35. 34)Rinaldi A, Kwee I, Poretti G, Mensah A, Pruneri G, Capello D, Rossi D, Zucca E, Ponzoni M, Catapano C, Tibiletti MG, Paulli M, Gaidano G & Bertoni F. Comparative genome wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. British Journal Haematology 2006; 134: 27-36.

  36. 35)Rinaldi A, Kwee I, Taborelli M, Largo C, Uccella S, Martin V, Poretti G, Gaidano G, Calabrese G, Martinelli G, Baldini L, Pruneri G, Capella C, Zucca E, Cotter FE, Cigudosa JC, Catapano CV, Maria GraziaTibiletti MG & Bertoni F. Genomic and expression profiling identifies the B cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. British Journal Haematology 2006; 132: 303-316.

  37. 36)Taborelli M, Tibiletti MG, Martin V, Pozzi B, Bertoni F & Capella C. Chromosome band 6q deletion pattern in malignant lymphomas. Cancer Genetics and Cytogenetics 2006;  165: 106-113.

  38. 37)Macagno A., Molteni M., Rinaldi A., Bertoni F., Lanzavecchia A., Rossetti C. & Sallusto F. A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression. The Journal of Experimental Medicine 2006; 203: 1481-1492.

  39. 38)Albertini V, Jain A, Vignati S, Napoli S, Rinaldi A, Kwee I, Nur-e-Alam M, Bergant J, Bertoni F, Carbone GM, Rohr J & Catapano CV. Novel GC-rich DNA binding compound produced by a genetically engineered mutant of the mithramycin producer S. Argillaceus exhibits improved  transcriptional repressor activity: implications for cancer therapy. Nucleic Acids Research 2006; 34: 1721-1734.

  40. 39)Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, Oldrini R, Capella C, Bertoni F, Carbone GM & Catapano CV. Cellular effects and transcriptional response to peroxisome proliferator-activated receptor γ activation in ovarian cancer cells. Neoplasia 2006; 8: 251-261.

  41. 40)Lacrima K, Valentini A, Lambertini C, Taborelli M, Rinaldi A, Zucca E, Catapano C, Cavalli F, Gianella-Borradori A, MacCallum DE & Bertoni F. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Annals of Oncology 2005; 16: 1169-1176.

  42. 41)Napolitani G, Rinaldi A, Bertoni F, Sallusto F & Lanzavecchia A. Selected TLR agonist combinations synergistically trigger dendritic cells with enhanced TH1 polarizing capacity. Nature Immunology 2005; 6: 779-776.

  43. 42)Chtanova T, Newton R, Liu S, Weininger L,Young TR, Silva DG, Bertoni F, Rinaldi A, Chappaz S, Sallusto F, Rolph MS & Mackay CR.  Identification of T cell-restricted responses, using a comprehensive collection of microarray datasets. The Journal of Immunology 2005; 175: 7837-7847.

  44. 43)Cogliatti SB, Bertoni F, Zimmermann DR, Henz S, Diss TC, Ghielmini M and  Schmid U. Igvh mutations in blastoid mantle cell cymphoma characterize a subgroup with tendency to a more favourable clinical outcome. Journal of Pathology 2005; 206: 320-327.

  45. 44)Ghielmini M, Hsu Schmitz S-F, Cogliatti S, Bertoni F, Waltzer U, Fey M, Betticher D, Schäfer H, Pichert G, Stahel R, Ketterer N, Bargetzi M & Cerny T. Effect of single agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma. Journal of Clinical Oncology 2005; 23: 705-711.

  46. 45)Laszlo D, Andrés JM Ferreri AJM, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L & Zucca E. Clinical activity of rituximab in gastric marginal zone (MALT) non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. Journal of Clinical Oncology 2005; 23: 1979-1983.

  47. 46)Martinelli G, Laszlo D, Agazzi A, Pruneri G, Bertoni F, Calabrese L & Martinelli G. In Reply to; “Persistent Residual Disease in t(11;18)(q21;q21) Positive Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Chemotherapy or Rituximab”. Journal of Clinical Oncology 2005; 23: 7363-7364.

  48. 47)Auer R,  Starczynski J, McElwaine  SM, Bertoni F, Newland A,  Fegan D & Cotter. Identification of a potential role for BOB-1 and PC3b in the 11q23 deletion of CLL. Genes, Chromosomes and Cancer 2005;43: 1-10.

  49. 48)Bertoni F, Conconi A, Cogliatti S, Hsu Schmitz SF, Ghielmini M, Cerny T, Fey M, Pichert G, Bertolini F, Ponzoni M, Baldini L, Jones C, Auer R, Zucca E, Cavalli & Cotter FE. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). British Journal of Haematology 2004; 124: 289-298.

  50. 49)Grossfeld PD, Mattina T, Lai Z, Favier R, Lyons Jones K, Cotter F, Jones C, and the 11q Consortium (Adam M, Bertoni F, Bellugi U, Bradshaw C, Chen J, Dell’Aquila M, Elias W, Haghi M, Hoffman H, Jockin Y, Lee Jones K, Jones M, Jones W, Lavine J, Ruiz-Lozano P, Magit A, Newton P, Nyhan W, Oakley D, O’Halloran H, Rothman A, Scher C, Tunnacliffe A, Zingale A). The 11q terminal deletion disorder:  A prospective study of 110 cases. American Journal of Medical Genetics Part A 2004: 129A: 51-61.

  51. 50)Fu W-N, Bertoni F, Kelsey SM, McElwaine SM, Cotter FE, Newland AC & Jia L. Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene 2003; 22: 451-455.

  52. 51)Favier R, Jondeau K, Boutard P, Grossfeld P, Reinert P, Jones C, Bertoni F, Cramer EM. Paris-Trousseau syndrome: clinical, hematological, molecular data of ten new cases. Thrombosis and Haemostasis 2003; 90:893-897.

  53. 52)Bertoni F, Conconi A, Capella C, Motta T, Giardini R, Ponzoni M, Pedrinis E, Domenico Novero D, Rinaldi P, Cazzaniga G, Andrea Biondi A, Wotherspoon A, Hancock W, Smith P, Souhami R, Cotter FE, Cavalli F & Zucca E. Molecular follow-up in gastric MALT lymphomas: early analysis from of the LY03 cooperative trial. Blood 2002; 99: 2541-2544.

  54. 53)Auer RL, Bertoni F, Jones C & Cotter FE. The Class II tumour suppressor gene RARRES3 maps to 11q12, not 11q23. Leukemia 2002; 16: 1396-1397.

  55. 54)Conconi A, Bertoni F, Pedrinis E, Motta T, Roggero E, Luminari S, Capella C, Bonato M, Cavalli F & Zucca E. Nodal marginal zone B cell lymphomas may arise from different subsets of marginal zone B lymphocytes. Blood 2001; 98: 781-786.

  56. 55)Bertoni F, Conconi A, Luminari S, Realini C, Roggero E, Baldini L, Carobbio S, Neri A, Cavalli F & Zucca E. Lack of CD95/FAS gene somatic mutations in marginal zone B-cell lymphomas. Leukemia 2000; 14: 446-448.

  57. 56)Luminari S, Intini D, Baldini L, Berti E, Bertoni F, Zucca E, Cro L, Maiolo AT, Cavalli F & Neri A. Analysis of BCL10 gene mutations in lymphoid malignancies. Leukemia 2000; 14: 905-908.

  58. 57)Roggero E; Zucca E, Mainetti C, Bertoni F, Valsangiacomo C, Pedrinis E, Borisch B, Piffaretti JC, Cavalli F & Isaacson PG. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Human Pathology 2000; 31: 263-268.

  59. 58)Ghielmini M, Schmitz SF, Bürki K, Pichert G, Betticher DC, Stupp R, Wernli M, Lohri A, Schmitter D, Bertoni F & Cerny T for the Swiss Group for Clinical Research (SAKK). The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Annals of Oncology 2000; 11 (suppl. 1): S123-S126.

  60. 59)Zucca E, Roggero E, Maggi-Solcà N, Conconi A, Bertoni F, Reilly I, Castelli D, Pedrinis E, Piffaretti JC & Cavalli F.Prevalence of Helicobacter pylori and Hepatitis C Virus (HCV) infections among non-Hodgkin's lymphoma patients in Southern Switzerland. Haematologica 2000; 85: 147-153.

  61. 60)Bertoni F, Conconi A, Carobbio S, Realini C, Codegoni AM, Zucca E & Cavalli F. Analysis of CD95/FAS gene somatic mutations in ovarian cancer cell lines. International Journal of Cancer 2000; 86: 450.

  62. 61)Bertoni F, Sanna P, Tinguely M, Roggero E, Conconi AR, Gisi M, Cazzaniga G, Biondi A, Pedrinis E, Cavalli F & Zucca E. Association of gastric and Waldayer's ring lymphoma: a molecular study. Hematological Oncology 2000; 18: 15-19.

  63. 62)Conconi A, Zucca E, Roggero E, Bertoni F, Bernasconi A, Mingrone W, Pedrinis E, Cavalli F. Prognostic models for diffuse large B-cell lymphoma. Hematological Oncology 2000; 18: 61-73

  64. 63)Bertoni F, Müllenbach R, Broggini M, Roggero E, Cavalli F, Cotter FE & Zucca E. Extranodal marginal zone B-cell lymphoma genotyping by ALU - polymerase chain reaction. Leukemia and Lymphoma 2000; 38: 605-610.

  65. 64)Bertoni F, Gisi M, Roggero E, Conconi A, Mingrone W, Cavalli F & Zucca E. Molecular detection of circulating neoplastic cells in patients with clinically localised gastric and non-gastric mucosa-associated lymphoid tissue lymphoma. Digestive Liver Disease 2000; 32: 188-191.

  66. 65)Bertoni F, Codegoni AM, Furlan D, Tibiletti MG, Capella C & Broggini M. Chk1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes, Chromosomes and Cancer 1999; 26: 176-180.

  67. 66)Furlan D, Bertoni F, Cerutti R, Taborelli M, Pinotti G, Roggero E, Cavalli F, Bonato M, Zucca E & Capella C. Microsatellite instability in gastric MALT lymphomas and in associated other neoplasms. Annals of Oncology 1999; 10: 783-788.

  68. 67)Bertoni F, Luminari S, Intini D, Carobbio S, Codegoni AM, Spataro V & Neri A. Analysis of BCL10 gene mutations in ovarian cancer cell lines. Annals of Oncology 1999; 10: 1259-1260.

  69. 68)Codegoni AM, Bertoni F, Patregnani C, Marinetti E, D'Incalci M & Broggini M. Allelic expression of p73 in human ovarian cancers. Annals of Oncology 1999; 10: 949-953.

  70. 69)Bertoni F, Zucca E, Genini D, Cazzaniga G, Roggero E, Ghielmini M, Cavalli F & Biondi A. Immunoglobulin light chain kappa deletion rearrangement as a marker of clonality in mantle cell lymphoma. Leukemia and Lymphoma, 1999; 36: 147-150.

  71. 70)Bertoni F, Roggero E, Luscieti P, Pedrinis E, Cavalli F & Zucca E. Clonality assessment in blood of patients with mantle cell lymphoma. Leukemia and Lymphoma 1999; 32: 375-379.

  72. 71)Bieri S, Roggero E, Zucca E, Bertoni F, Pianca S, Sanna P, Pedrinis E, Bernier J & Cavalli F. Primary mediastinal large B-cell lymphoma (PMCL): the need for prospective clinical trials. Leukemia and Lymphoma 1999; 35: 139-46.

  73. 72)Codegoni AM, Bertoni F, Colella G, Caspani G, Grassi L, D'Incalci M & Broggini M. Microsatellite instability and frameshift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancer. Oncology Research 1999, 11: 297-301.

  74. 73)Zucca E, Bertoni F, Roggero E, Bosshard G, Cazzaniga G, Pedrinis E, Biondi A & Cavalli F. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to MALT lymphoma of the stomach. New England Journal of Medicine 1998; 338: 804-810.

  75. 74)Zucca E, Bertoni F, Roggero E, Cazzaniga G, Bosshard G, Biondi A & Cavalli F. Autoreactive B-cell clones in marginal-zone B-cell lymphoma (MALT lymphoma) of the stomach. Leukemia 1998; 12: 247-249.

  76. 75)Baldini L, Blini M, Guffanti A, Fossati V, Colombi M, Bertoni F, La Targia ML, Motta M, Neri A & Bertoni G. Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa. Annals of Oncology 1998; 9: 779-781.

  77. 76)Sanna P, Bertoni F, Zucca E, Roggero E, Passega Sidler E, Fiori G, Pedrinis E, Mombelli G & Cavalli F. Cardiac involvement in primary extranodal HIV-related lymphoma of the liver: a case report and short review of the literature. Annals of Haematology 1998; 77: 75-78.

  78. 77)Foa P, Massaro P, Caldiera S, La Targia ML, Iurlo A, Clerici C, Fornier M, Bertoni F & Maiolo AT. Long term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera. European Journal of Haematology 1998; 60: 273-277.

  79. 78)Bertoni F, Sanna P, Zucca E, Roggero E & Cavalli F. Primary extranodal lymphoma of skeletal muscles: a report of four cases and discussion of the literature. Oncology Reports 1998; 5: 605-607.

  80. 79)Bertoni F, Cazzaniga G, Bosshard G, Roggero E, Barbazza R, De Boni M, Capella C, Pedrinis E, Cavalli F, Biondi A & Zucca E. Immunoglobulin heavy chain D gene rearrangement pattern indicates that the MALT type gastric lymphoma B-cells have undergone an antigen selection process. British Journal of Haematology 1997; 97: 830-836.

  81. 80)Bertoni F, Bosshard G, Roggero E, Ceresa E, Cavalli F & Zucca E. Clinical relevance of BCL-2(MBR)/JH rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma. British Journal of Cancer 1997; 76: 36-39.

  82. 81)Pinotti G, Zucca E, Roggero E, Pascarella A, Bertoni F, Savio A, Savio E, Capella C, Pedrinis E, Saletti PC, Capella C, Morandi E, Santandrea G & Cavalli F. Clinical features, treatment outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leukemia and Lymphoma 1997; 26: 527-537.

  83. 82)Sanna P, Bertoni F, Roggero E, Quattropani C, Rusca T, Pedrinis E, Monotti R, Mombelli G, Cavalli F & Zucca E. Angiotropic (intravascular) lymphoma: a case report and short review of the literature. Tumori 1997; 83: 772-775.

  84. 83)Foa P, Iurlo A, Orazi A, Saglio G, Ribera S, Bertoni F, Caldiera S, Fornier M & Maiolo AT. Biological determinants of long-term survival in chronic myelogenous leukemia patients treated with conventional chemotherapy. Acta Haematologica 1997; 97: 187-188.

  85. 84)Iurlo A, Fornier M, Caldiera S, Bertoni F & Foa P. Palmar-plantar erythrodysaesthesia syndrome due to 5-fluorouracil therapy--an underestimated toxic event? Acta Oncologica 1997; 36: 653-654

  86. 85)Zucca E, Bertoni F, Bosshard G, Roggero E, Ceresa E, Sanna P, Pedrinis E & Cavalli F. Clinical significance of bcl-2 (mbr) /JH rearrangement in the peripheral blood of patients with diffuse, large B-cell lymphomas. Annals of Oncology 1996; 7: 1023-1027.

  87. 86)Foa P, Iurlo A, Ribera S, Da Milano I, Caldiera S, Fornier M, Bertoni F & Maiolo AT. Chronic myeloid leukemia treated with busulfan: relationship between total amount of drug required during the first year of treatment and duration of chronic phase. Oncology Reports 1996; 3: 1067-1069.

  88. 87)Foa P, Pomati M, Ribera S, Caldiera S, Bertoni F, Fornier M & Maiolo AT. Fluorescence in situ hybridization (FISH) for evaluating residual disease in Philadelphia chromosome-positive chronic myeloid leukemia during interpheron alpha therapy. Oncology Reports 1996; 3: 847-849.